Patients taking oral bisphosphonates for the first time may be at higher risk of developing scleritis and uveitis, according to a large, retrospective cohort study published online April 2 in the Canadian Medical Association Journal. The incidence rate among 10,827 first-time bisphosphonate users was 29/10,000 person-years for uveitis and 63/10,000 person-years for scleritis. In contrast, the incidence rate among 923,320 nonusers was 20/10,000 person-years for uveitis and 36/10,000 for scleritis. This resulted in an elevated risk for uveitis among first-time users (adjusted relative risk [RR], 1.45; 95% confidence interval [CI], 1.25 - 1.68) and scleritis (adjusted RR, 1.51; 95% CI, 1.34 - 1.68). The researchers also found that bisphosphonate users were older and more likely to be women compared with nonusers.
To see more details visit, www.medscape.com
